Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.17 Consensus PT from Analysts

Context Therapeutics Inc. (NASDAQ:CNTX) has been assigned an average rating of “Moderate Buy” from the ten brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $6.1667.

A number of analysts have recently commented on CNTX shares. Lifesci Capital downgraded Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Maxim Group reduced their price target on Context Therapeutics from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, June 16th. Citigroup reissued an “outperform” rating on shares of Context Therapeutics in a report on Thursday, August 6th. Wall Street Zen lowered Context Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 20th. Finally, Weiss Ratings raised shares of Context Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 20th.

Context Therapeutics Price Performance

NASDAQ CNTX opened at $0.39 on Tuesday. The company has a market capitalization of $35.81 million, a PE ratio of -0.81 and a beta of 1.74. The company has a fifty day moving average of $0.56 and a 200 day moving average of $1.72. Context Therapeutics has a 1 year low of $0.37 and a 1 year high of $3.62.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.06). Research analysts expect that Context Therapeutics will post -0.45 earnings per share for the current year.

Institutional Trading of Context Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CNTX. Blue Owl Capital Holdings LP increased its holdings in Context Therapeutics by 0.3% in the fourth quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock valued at $10,926,000 after buying an additional 25,000 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of Context Therapeutics during the 2nd quarter worth about $3,417,000. Octagon Capital Advisors LP acquired a new stake in shares of Context Therapeutics during the 1st quarter valued at about $13,755,000. Vanguard Group Inc. grew its position in shares of Context Therapeutics by 4.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock valued at $3,387,000 after acquiring an additional 134,449 shares during the period. Finally, Millennium Management LLC acquired a new stake in shares of Context Therapeutics during the 4th quarter valued at about $3,824,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.